SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes
Highlights
– Nationwide active-comparator cohort (Taiwan NHID) compared SGLT2 inhibitors (n=148,354) with DPP‑4 inhibitors (n=322,703) for risk of new-onset atopic dermatitis (AD).
– SGLT2i use associated with lower AD incidence (9.742 vs 12.070 per 1,000 person‑years) and reduced risk (IPTW-adjusted HR 0.847) versus DPP‑4i.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.